NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- According to a new research report titled “Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, CDK inhibitors currently exhibits a strong pipeline with 24 drug candidates.
Access Report Summary at: https://www.psmarketresearch.com/market-analysis/cdk-inhibitors-therapeutics-pipeline-analysis
The study analyzed that the CDK inhibitors therapeutics pipeline comprises approximately 24 drug candidates in different stages of development. CDKs are the catalytic subunits of serine or threonine protein kinases that regulate the checkpoints in the cell cycle to control the proliferative capacity of cancerous cells. These proteins form cyclin-CDK complex which gets activated after phosphorylation, leading to cell proliferation.
According to the research findings, most of the drug candidates of CDK inhibitors therapeutics pipeline are being developed to be administered by oral route.
USFDA granted Breakthrough Therapy Designation to a drug candidate of Eli Lilly and Company which is being developed for the treatment of refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. This will facilitate the development and expedite the review of drug candidate for the treatment of refractory HR+ advanced or metastatic breast cancer.
Make Enquiry Before Buying: https://www.psmarketresearch.com/send-enquiry?enquiry-url=cdk-inhibitors-therapeutics-pipeline-analysis
Eli Lilly and Company and Boehringer Ingelheim GmbH entered into a collaboration for clinical studies of their drug candidates in combination, in patients diagnosed with HR+, HER2-metastatic breast cancer.
Some of the key players developing drugs as CDK inhibitors for the treatment of various indications include Eli Lilly and Company, Merck & Co., AstraZeneca plc and others.
Explore Related Research
Lysosomal Storage Disorder Therapeutics Pipeline Analysis 2017
Drug manufacturing companies are constantly involved in the quest to find better and new treatment strategies with potential enzyme replacement therapies such as N-acetylglucosaminidase alpha (NAGLU) replacement which can also prove to be effective in Sanfilippo syndrome type B treatment. Various companies are developing drug candidates using different technologies for the development of effective and better drugs, which is driving the growth of the pipeline.
https://www.psmarketresearch.com/market-analysis/lysosomal-storage-disorders-pipeline-analysis
Spinal Muscular Atrophy (SMA) Therapeutics Pipeline Analysis 2017
Spinal muscular atrophy is a rare inherited genetic disease that is characterized by loss of nerve cells, known as motor neurons. Motor neurons receive the nerve impulses, which are transmitted from the brain to the spinal cord and, further transmits these impulses to the muscles with the help of peripheral nerves. The loss of motor neurons can lead to atrophy and weakness in the muscles, that are closest to the trunk of the body such as back, hips and shoulders. Spinal muscular atrophy is mainly caused due to the mutation in the SMA2 and SMN1 genes in chromosome. Any mutation in SMA1 gene can lead to spinal muscular atrophy.
Post-Traumatic Stress Disorder (PTSD) Therapeutics Pipeline Analysis, 2017
Considerable growth is expected in the PTSD therapeutic pipeline, attributed to increasing prevalence of the disease, further aggravated by stressful lifestyle. Funds from the various non-profit organization such as, PTSD Foundation of America, Anxiety and Depression Association of America, Defense Centers of Excellence for Psychological Health & Traumatic Brain Injury. are supporting the development of therapeutic pipeline of the disease. Increasing collaboration between educational institutes and pharmaceutical companies is also one of the factors for growth of PTSD pipeline.
https://www.psmarketresearch.com/market-analysis/ptsd-therapeutics-pipeline-analysis
About P&S Market Research
P&S Market Research is a market research company, which offers market research and consulting services for various geographies around the globe. We provide market research reports, industry forecasting reports, business intelligence, and research based consulting services across different industry/business verticals.
As one of the top growing market research agency, we’re keen upon providing market landscape and accurate forecasting. Our analysts and consultants are proficient with business intelligence and market analysis, through their interaction with leading companies of the concerned domain. We help our clients with B2B market research and assist them in identifying various windows of opportunity, and framing informed and customized business expansion strategies in different regions.
Contact:
Kundan Kumar
Manager – Client Partner
347, 5th Ave. #1402
New York City, NY - 10016
Toll-free: +1-888-778-7886 (USA/Canada)
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com